ReviewMetabolites2026
The Gut-Vascular Axis as a Therapeutic Hub: Rationale and Evidence for Combined Gut-Directed and Endothelium-Directed Interventions.
Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe gut-vascular axis linking gut microbiota, intestinal barrier, and vascular endothelium is a key pathophysiological interface in chronic metabolic diseases. Dysbiosis and "leaky gut" enable bacterial products and gut-derived metabolites to enter the circulation, driving systemic inflammation and endothelial dysfunction. Single-target interventions show limited efficacy; combined gut-directed and endothelium-directed strategies remain underexplored.
methodsPubMed was searched from database inception to 31 August 2026 using a predefined search strategy combining terms for the gut-vascular axis, intestinal barrier, microbiota/metabolites, endothelial dysfunction, and combined interventions. Preclinical and clinical studies evaluating gut barrier integrity, microbiota modulation, or endothelial protection, alone or in combination, were included. No formal risk-of-bias scoring was performed; study design, sample size, endpoint type, follow-up, and limitations were appraised.
results(1) The axis comprises three core components: gut barrier, endothelium, and microbial metabolites. (2) Pathological activation involves leaky-gut-driven endotoxemia, dysbiosis-induced metabolic inflammation, and immune crosstalk sustaining vascular inflammation. (3) Animal models demonstrate that combined interventions can reduce atherosclerotic plaque, improve endothelium-dependent relaxation, and lower systemic inflammation to a greater extent than some monotherapies; however, most studies have not directly compared combination therapy with both corresponding monotherapies or performed formal interaction testing, so true synergy remains unproven. (4) Limited clinical studies in metabolic syndrome and heart failure suggest improvements in surrogate endpoints, but large-scale randomised trials with hard cardiovascular endpoints are lacking.
conclusionsThe gut-vascular axis is a promising therapeutic framework for cardiometabolic diseases, with a strong biological rationale. Combined gut- and endothelium-directed interventions offer a rational multi-target approach, but direct evidence that they provide superior clinical outcomes remains limited. Future research must prioritise hard-endpoint trials, standardised interventions and endpoints, long-term safety, reproducibility, multi-omics-based patient stratification, and next-generation microbiome therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.